NYXH nyxoah.com: Company Value to Revenue

The EV/Sales ratio reflects the expansion dynamics of Nyxoah S.A. (NYXH) across US and European markets, where the value of 1660.00 serves as the current metric. Nyxoah S.A. develops autonomous neurostimulators for the control of sleep-disordered breathing. The advantage of compact implants over bulky alternatives enables the brand to maintain pricing power for both its devices and surgical procedures.
NYXH (Nyxoah S.A): analytical breakdowns and indicator data

Nyxoah S.A. is developing apnea treatment systems through partnerships with specialized clinics and research centers. This EV/Sales chart allows for an assessment of how the market capitalizes these technological advancements. The metric compares the total enterprise value, adjusted for net debt, against the volume of generated revenue. This reveals the real value of the business regardless of the debt load. The stability of this indicator confirms the asset's fundamental resilience and protects the investor from overpaying.